Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ:ELDN) announced it will host an R&D Day on July 9, 2025 in New York City, starting at 8:30 am ET. The event will showcase the company's lead investigational candidate, tegoprubart, focusing on its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial.

The R&D Day will feature presentations from Eledon's executive team and leading transplantation experts from prestigious institutions. Topics will cover unmet needs in solid organ transplantation, clinical endpoint evolution, and strategic opportunities in islet cell transplantation and xenotransplantation. The event will conclude with a Q&A session and will be available via live webcast.

IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET.

The event will feature members of Eledon’s executive team and the following leading experts in transplantation:

• Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
• John D. Cleveland, M.D., Associate Professor of Clinical Surgery, Program Director, Congenital Cardiac Surgery Fellowship, Children’s Hospital Los Angeles, Department of Surgery, Keck School of Medicine
• William E. Fitzsimmons, Pharm.D., M.S., Adjunct Professor, University of Illinois Colleges of Medicine and Pharmacy; Executive Committee, Transplant Therapeutics Consortium
• Piotr Witkowski, M.D., Ph.D., Professor of Surgery and Director of the Pancreatic and Islet Transplant Program at UChicago Medicine

The R&D Day event will highlight Eledon’s lead investigational candidate, tegoprubart, with a focus on its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial. Additional sessions will address unmet needs in solid organ transplantation, the evolution of clinical endpoints such as iBox and eGFR, and the Company’s strategic opportunities in islet cell transplantation and xenotransplantation. The program will conclude with a live Q&A session featuring Eledon’s management team and invited key opinion leaders.

To register for the in-person event, please email: claire.mccardell@gilmartinir.com. A live webcast of the event and presentation materials will be available on the “Events” section of Eledon’s website at www.eledon.com.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

When and where is Eledon Pharmaceuticals (ELDN) hosting its R&D Day 2025?

Eledon will host its R&D Day on July 9, 2025 in New York City, beginning at 8:30 am ET.

What topics will be covered at Eledon's (ELDN) R&D Day 2025?

The event will focus on tegoprubart clinical development in organ and cell transplantation, the Phase 2 BESTOW trial, unmet needs in solid organ transplantation, clinical endpoints, and opportunities in islet cell transplantation and xenotransplantation.

Who are the key speakers at Eledon's (ELDN) R&D Day 2025?

Speakers include Eledon's executive team and transplantation experts: Dr. Andrew Adams from University of Minnesota, Dr. John Cleveland from Children's Hospital Los Angeles, Dr. William Fitzsimmons from University of Illinois, and Dr. Piotr Witkowski from UChicago Medicine.

How can investors attend or access Eledon's (ELDN) R&D Day 2025?

Investors can attend in-person by emailing claire.mccardell@gilmartinir.com or access the live webcast through the 'Events' section of Eledon's website at www.eledon.com.